Dr. Michael R. Jaff, Vice President of Clinical Affairs, Innovation, Technology, and Peripheral Interventions at Boston Scientific, is a world-renowned vascular medicine expert. In this video Dr. Jaff discusses the Primary Results of the Randomized Trial of Eluvia DES vs Bare Metal Stents.Link to Abstract-https://clinicaltrials.gov/ct2/show/study/NCT02921230The EMINENT research is a prospective, multi-center trial that found the ELUVIA stent to be more effective than self-expanding bare nitinol stents in treating femoropopliteal artery lesions.The EMINENT research is a prospective, multi-center study that found the ELUVIA stent to be more successful than Self-Expanding Bare Nitinol Stents in treating lesions 30-210 mm length in the femoropopliteal arteries in people with Rutherford classifications 2-4 symptoms.The experiment is a controlled, single-blind, 2:1 randomized (ELUVIA vs. Self-Expanding Bare Nitinol Stents) superiority trial (RCT).The study's goal is to confirm the greater effectiveness of the ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) in treating SFA and/or PPA lesions up to 210 mm in length when compared to bare metal stents, as well as collect other data, such as health economics data. - Cardiology - 566_600c9efaa3c99

Michael Jaff, DO- Primary Results of the Randomized Trial of Eluvia DES vs Bare Metal Stents @docmrjaff @bsc_pi #EluviaDES #Eluvia #EMINENT #BSC #PAD

Michael Jaff, DO- Primary Results of the Randomized Trial of Eluvia DES vs Bare Metal Stents @docmrjaff @bsc_pi #EluviaDES #Eluvia #EMINENT #BSC #PAD

2 weeks
30 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Dr. Michael R. Jaff, Vice President of Clinical Affairs, Innovation, Technology, and Peripheral Interventions at Boston Scientific, is a world-renowned vascular medicine expert. In this video Dr. Jaff discusses the Primary Results of the Randomized Trial of Eluvia DES vs Bare Metal Stents.

Link to Abstract-
https://clinicaltrials.gov/ct2/show/study/NCT02921230

The EMINENT research is a prospective, multi-center trial that found the ELUVIA stent to be more effective than self-expanding bare nitinol stents in treating femoropopliteal artery lesions.

The EMINENT research is a prospective, multi-center study that found the ELUVIA stent to be more successful than Self-Expanding Bare Nitinol Stents in treating lesions 30-210 mm length in the femoropopliteal arteries in people with Rutherford classifications 2-4 symptoms.

The experiment is a controlled, single-blind, 2:1 randomized (ELUVIA vs. Self-Expanding Bare Nitinol Stents) superiority trial (RCT).

The study's goal is to confirm the greater effectiveness of the ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) in treating SFA and/or PPA lesions up to 210 mm in length when compared to bare metal stents, as well as collect other data, such as health economics data.

Up Next Autoplay